Combination Treatment Improves Relapse-Free Survival Time
Source: Dermatology Times, March 2021
Patients with stage III melanoma receiving a combination treatment of dabrafenib (Tafinlar) and trametinib (Mekinist) achieved longer restricted mean survival times (RMST) compared to placebo, according to recent study results.1
These findings not only suggest that patients receiving the combined treatment could remain relapse free for an average of 13 additional months over 5 years versus those receiving placebo, but they also open the door to further exploration of these adjuvant treatments.